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Abstract
C-150 a Mannich-type curcumin derivative, exhibited pronounced cytotoxic effects against
eight glioma cell lines at micromolar concentrations. Inhibition of cell proliferation by C-150
was mediated by affecting multiple targets as confirmed at transcription and protein level.
C-150 effectively reduced the transcription activation of NFkB, inhibited PKC-alpha which
are constitutively over-expressed in glioblastoma. The effects of C-150 on the Akt/ Notch
signaling were also demonstrated in a Drosophila tumorigenesis model. C-150 reduced the
number of tumors in Drosophila with similar efficacy to mitoxantrone. In an in vivo orthotopic
glioma model, C-150 significantly increased the median survival of treated nude rats com-
pared to control animals. The multi-target action of C-150, and its preliminary in vivo efficacy
would render this curcumin analogue as a potent clinical candidate against glioblastoma.
Introduction
Malignant glioma is the most common cancer of the central nervous system in adults with a
median survival time of nine months following surgery, radiotherapy and chemotherapy.
Despite advances in different therapies of glioblastoma, they are associated with significant
side effects and only limited efficacy [1]. More effective therapeutic agents with fewer side
effects are urgently needed.
Since cancer arises via multiple pathological or signaling pathways, natural compounds or
their derivatives have the potential to be developed into optimum pharmaceuticals for cancer
because of their multi-function and multi-target characteristics. Many pieces of evidence point
out the relevance of herbal medicines for cancer therapy and prevention, including polyunsatu-
rated fatty acids [2–4], corosolic acid [5] and dietary phytochemicals among others [6–8].
Recent attention has focused on curcumin, also known as diferuloyl methane, a polyphenolic,
yellow pigment found in the rhizome of turmeric (Curcuma longa). It has been attributed
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antioxidant, anti-inflammatory, anti-angiogenic and anti-proliferative properties [9–10]. A
number of preclinical and clinical studies suggest that curcumin may represent a novel strategy
to treat cancer patients alone or in combination with already existing therapeutic regimens [9,
11]. Although recent advances in formulation show promise, the in vivo application of curcu-
min has been limited for its low potency and unsatisfactory pharmacokinetics [12, 13]. This
necessitates the search for new formulation solutions and the synthesis of novel curcumin ana-
logues with a similar safety profile, but improved pharmacological properties.
Different synthetic concepts have been therefore developed to expand the molecular diver-
sity, from the side-chain and diketone transformations to alkyl and alkenyl functionalizations
on C-4 in the central position of curcumin [14–16]. According to previous studies, modifica-
tion at 4-position of curcumin enhanced its potency and selectivity and is playing a pivotal role
in various biological activities including anti-inflammatory and anti-androgenic activities, and
cytotoxicity [15]. Another series of curcumin analogues with different substituents at the
4-position of the phenyl group were synthesized and found active against human glioblastoma
cell line [16]. Here, we describe a Mannich-type curcumin analogue C-150 (Fig 1), possessing
meta-hydroxyphenyl side-chains and β-phenyl-β-acrylamido branched central motif, which
was more potent than curcumin in suppressing proliferation of different glioma cell lines [17,
18].
The potential application of curcumin in neuro-oncology was suggested previously by
authors who showed efficacy of this natural compound in cellular as well as in vivomodels
[19–25]. Curcumin has been shown to have multiple anticancer effects, including inhibition of
proliferation, induction of apoptosis, and inhibition of angiogenesis [26, 27], but it also induces
apoptosis-independent cell death [28]. Evidence indicates that the anticancer effects of curcu-
min and its structural derivatives are dependent on their capacity of modulating multiple
molecular targets, including transcription factors, growth factors, kinases, inflammatory
Fig 1. The chemical structure of curcumin and C-150. Curcumin 1: (1E,4Z,6E)-5-hydroxy-1,7-bis
(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one, a related cytotoxic analogue that showed efficacy
against glioma 2, N,N'-(((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-
4,1-phenylene))diacetamide and C-150 3, N-((E)-5-(3-hydroxyphenyl)-2-((E)-3-(3-hydroxyphenyl)acryloyl)-
3-oxo-1-phenylpent-4-en-1-yl)acrylamide.
doi:10.1371/journal.pone.0149832.g001
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cytokines, adhesion molecules, apoptosis-related proteins [26], and signaling pathways such as
NF-κB, AKT, MAPK, Wnt, Notch, p53 and Jak/Stat3 [24, 27, 29, 30]. Here, we demonstrated
that C-150, a curcumin analogue also acts on multiple targets at the transcription and protein
level at significantly lower concentrations than the original compound.
Tumor cells, including glioblastoma cells are more sensitive to endoplasmic reticulum (ER)
stress inducing agents than normal cells as their ER-stress response is continuously engaged,
due to their chronic stress situation, leading to activation of pro-apoptotic signals and finally
tumor cell death. Preclinical development of novel anti-glioma drugs targeting the ER-stress
response has been recently reviewed [19]. In this paper fast activation of ER-stress by curcumin
and its derivative was confirmed by inducing GRP78 and GADD153 protein expression.
Curcumin has been shown to increase the concentration of reactive oxygen species which
causes ER-stress, and caspase 3-dependent and -independent apoptosis through the release of
cytochrome C and apoptosis inducing factor from the mitochondria, and inhibition of AKT
[24, 31]. AKT is a downstream serine/threonine kinase in the RTK/PTEN/PI3K pathway. The
activated AKT and phospho-AKT levels are elevated in the majority of glioblastoma cell lines
and tumor samples, therefore inhibitors of the Akt pathway represent a potential treatment
option against glioblastoma [32]. It was also suggested that curcumin inhibition of AKT/
mTOR/S6K signaling pathway may be related to its induction of autophagy in malignant gli-
oma cells [33].
The effects of C-150 on the Akt/Notch signaling were also demonstrated in a Drosophila
cancer model, where malignant transformation occurs in the eye based on a double Akt/Notch
„gain-of-expression”mutant strain [34]. This in vivomodel can be used for testing curcumin
analogs for their potency on modulating the Akt/Notch signaling, and could provide their first
in vivo proof of concept results for potential anticancer agents. Since, this model cannot be
translated directly to human therapy, mainly because of the differences in ADME parameters
we also investigated the effects of C-150 in an in vivo glioma model.
Results and Discussion
Cytotoxic effects of C-150 in glioblastoma cells
The cytotoxicity of C-150 curcumin analogue was assessed in a panel of human glioblastoma
cell lines (namely: GBM1-6, U87 MG, U251 MG and U373 MG) using the MTS assay. IC50 val-
ues for 48 h exposure were summarized in Fig 2. Although the effect of curcumin was reported
previously on a few glioma cells, it was included here to evaluate its cytotoxicity in other glioma
cells and to provide a comparison with the new analogue.
C-150 exhibited pronounced cytotoxic effects against all glioma cell lines at micromolar con-
centrations. Between the most sensitive cell line U251MG (IC50: 0.33 μM) and the most resistant
cell line U373MG (IC50:>5 μM) there was at least a 15-fold difference in case of C-150.
To visualize the cytotoxic effects of C-150 holographic microscopy analysis (HoloMonitor
3M, Phiab, Sweden) was also performed [35, 36]. This technology is label-free and non-inva-
sive, it detects only the effects of the tested compound [37]. These experiments record morpho-
logical parameters of treated cells such as area, thickness and volume. We incubated four
different glioma cell lines (U87 MG, U-251 MG, GBM1, GBM2) with 1.0 μMC-150 and holo-
graphic images were taken before and 24 h after treatment. C-150 induced cell death after 24 h
treatment is illustrated with holographic images in Fig 3. Decrease in cellular area and the
increase of average thickness could be registered after treatment, in case of all four treated cell
lines as a hallmark of cell death (cell rounding and detachment from the surface, Fig 3). It is the
first time where the effects of drug induced cell death on cellular morphology of these glioma
cells were detected by using 3D holographic images.
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Multiple targets of C-150
Biochemical and in vitro assays. Curcuminoids have been reported to interact with multi-
ple molecular targets, such as NF-kB, STATs, AP-1, PPAR-g, etc. [26, 27, 29, 30]. Our aim was
to compare the effects of curcumin and C-150 on different cellular targets.
Curcumin was found to be a potent inhibitor of the activation of nuclear factor-kB (NF-κB)
and activated protein-1 (AP-1) in glioblastoma cells [21]. NF-κB proteins influence the expres-
sion of genes that are involved in a large number of physiological processes including immune
response, cell survival, differentiation, and proliferation [38]. One of the predominant targets
of curcumin is the NF-κB cell signaling pathway [39]. Moreover, correlation between NF-κB
inhibitory potential of different curcumin analogs and their cytotoxicity has been recently
reported [40]. In our study using a TNFα-induced luciferase gene expression model, the effects
of C-150 and curcumin was studied (see Fig 4). C-150 exhibited a very potent inhibition: it
Fig 2. Cytotoxic effects of curcumin and C-150 on nine different human glioma cell lines determined by MTS assay. IC50 values (μM) for C-150 and
curcumin are indicated in the table.
doi:10.1371/journal.pone.0149832.g002
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inhibited NF-κB activation at micromolar concentration (IC50 = 2.16±0.02 μM). This value is
26-times lower than that of curcumin (IC50 = 56.98±7.79 μM). Similar differences in cytotoxic
potential could be recorded between curcumin and its derivative C-150 against glioma cells
(see Fig 2).
There is increasing evidence that ER stress plays a crucial role in the regulation of apoptosis.
Recent studies suggested that curcumin-induced apoptosis may be mediated by oxidative and
ER stress signaling in several cancer cell types [41, 42]. The unfolded protein response (UPR)
consists of a set of adaptive pathways that are triggered by different perturbations in normal
function of the ER that lead to the production of misfolded proteins. The UPR alleviates ER
stress by up-regulation of chaperones and folding enzymes, degradation of misfolded proteins,
and arresting general translation. During this response, several pro-survival and pro-apoptotic
signals are activated and depending on the extent of the ER stress, cells survive or when ER
functions are severely impaired, they undergo apoptosis [43]. The UPR involves the activation
of several proteins, including the glucose-regulated protein 78 (GRP78/BiP), which represents
Fig 3. Holographic microscopic analysis of C-150 induced cell death. Tumor cells (U87 MG, U-251 MG, GBM1, GBM2) were treated with 1 μMC-150.
Cell volume, area and average thickness data are presented for each cell line 24 h after treatment. Error bars represent the standard error of means (SEM).
Statistical significance:* p<0.05 and ** p<0.01 (unpaired, two tailed Student’s t-test).
doi:10.1371/journal.pone.0149832.g003
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the pro-survival arm of the UPR. On the other hand, the CCAAT/enhancer binding protein
(CHOP/GADD153) transcription factor is one of the critical executioners of the pro-apoptotic
arm of the UPR [44]. When cells are experiencing ER stress GADD153 is induced and hence
initiating the cell death process.
As shown in Fig 5A, protein expression of GRP78 was increased 6 h after C-150 treatment,
while a significant increase could be observed in the curcumin-treated group at 25 μM concen-
tration, which is approximately 50-times the dose of C-150. Similar values were reported by
Pae et al. They found that curcumin-induced apoptosis of HL-60 leukemia cells was associated
with modulation of ER stress-related proteins after treatment with curcumin at 20 μM [42].
Western blotting analysis further showed that GADD153 protein expression was markedly
increased 6 h after C-150 treatment. It can be seen in Fig 5A, that C-150 induced GADD153
protein expression in a dose-dependent manner. Similarly, GADD153 expression was also
detected in curcumin-treated cells at 25 μM concentration. Scott and his co-workers also indi-
cated that curcumin induced GADD153 upregulation in colon cancer cells at 20 μM concentra-
tion [45].
The effect of curcumin and C-150 on GRP78, the protective component of the UPR, as well
as on GADD153, the pro-apoptotic arm of the UPR, were examined by QRT-PCR to determine
whether these compounds would be implicated in ER stress or UPR levels. As shown in Fig 5B,
GRP78 was up-regulated by an average of 3-fold, while GADD153 expression was induced by
14-fold in C-150 treated U87 MG cells, whereas no induction of these genes was detected in
case of curcumin at 10 μM. The activity of the pro-survival and pro-apoptotic component sug-
gest that in these conditions the cell survival signals mediated by GRP78 were overwhelmed by
the activity of the pro-apoptotic GADD153 activity sending the cells toward an apoptotic fate.
Similar observations were described in a rat retinal detachment model by Liu and coworkers
[46].
Several factors are known to be responsible for ER stress mediated transcriptional activation
of GRP78, including XBP-1 and activated ATF-4. ATF-4 is a cAMP response element-binding
transcription factor (CREB) and promotes cell survival by activating certain gene transcription
including those involved in the UPR and ER stress response [47].
Fig 4. Inhibitory effect of curcumin or C-150 on NF-κB activation. IC50 values obtained in an in vitro NF-
κB activation inhibition assay (C: curcumin, C-150: novel curcumin analog). Error bars represent standard
deviation from repeated experiments.
doi:10.1371/journal.pone.0149832.g004
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When we investigated whether XBP-1 and ATF-4 transcription was affected by C-150, we
found that 0.5 μMC-150 treatment up-regulated ATF4 2-fold and XBP-1 by almost 4-fold at
the mRNA level. We then tested whether this observation was applicable to 10 μM curcumin,
as well, but no induction could be registered for either of these genes at this concentration.
In summary, the ER could be a direct target site of C-150 or C-150 may indirectly elicit ER
stress acting through other cellular pathways. Our results demonstrated the capacity of C-150
to activate key genes and their protein products in initiation and execution phases of ER stress
and subsequently apoptosis at low- and sub-micromolar concentrations.
The effects of C-150 on kinase inhibition was also studied on a kinase panel consisting of 28
different kinases (RET, ROCK 2, SRC, SYK, TIE2, mTOR, PAK1, PAK4, PDGFRbeta, PIM1,
IKKbeta, IRAK4, InsR, JAK3, JNK1, c-MET, CSK, DDR1, ERBB2, FGFR3, B-RAF, CDK2/
CYCA, CDK4/CycD1, CHK1, cKIT, ABL, AKT1, AURA, AXL, FLT3, VEGFR2, TrkA, PKC-
alpha) (Fig 6). Preliminary screening of C-150 was performed at 1 μM concentration to assess
Fig 5. Effects of C-150 and curcumin on protein and gene expression. Effects of C-150 and curcumin on
GRP78 and GADD153 protein expression (a). U87 MG glioma cells were treated with compounds at the
indicated concentrations for 6 h. Cells were collected and the total lysates isolated and examined byWestern
blot analysis using an anti-GRP78 or anti-GADD153 specific antibody. Actin is shown as a control for equal
loading. (b) Induction of mRNA levels of genes involved in UPR and ER-stress (ATF4, XBP-1, GRP78 and
GADD153) as verified by using QRT-PCRmethod in U87 MG cells. Fold changes are shown for curcumin
(10 μM) and C-150 (0.5 μM) treated cells 6 h post-treatment, relative to untreated controls. Statistical
significance: * p<0.05 and ** p<0.01
doi:10.1371/journal.pone.0149832.g005
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possible specific kinase inhibition. Under this condition C-150 exhibited significant inhibition
(32.8%) only with PKC-alpha. This result of course, does not mean that C-150 does not interact
with other kinases in the panel at higher concentrations, or other kinases which are not present
in the list. Among many intracellular signaling proteins, protein kinase C (PKC) isoenzymes
have been identified as possible drug targets against tumor cells. PKC-alpha expression in ner-
vous system tumors, including glioblastoma has been reviewed recently [48]. In pre-clinical
experiments aprinocarsen, an antisense oligonucleotide targeting PKC-alpha had demon-
strated anti-tumor activity, in particular in animal models of glioblastoma. The inhibition of
PKC-alpha by C-150 could act synergistically with its other targets. This multi-target action
would render this curcumin analogue a potent clinical candidate against glioblastoma as tumor
cells cannot develop resistance easily.
In vivo target validation. The activated AKT pathway supports glioma cells to evade apo-
ptosis and enhance their invasion potency, by amplification of growth signals, thereby making
inhibition of AKT an attractive target for chemotherapy against glioblastoma [32, 33]. Several
studies reported that curcumin inhibits cancer cell proliferation by modulating Akt/mTOR sig-
naling [33, 49]. A recent study by Li et al. suggested that activity of curcumin is at least partly
mediated through inactivation of the Notch signaling pathway [50]. Notch signaling and the
PI3K-AKT pathway has been shown to synergize in vivo in a Drosophila melanogaster model
of Notch-induced tumorigenesis [34]. When the Notch ligand Delta was overexpressed, and
the „gain-of-expression”mutation of the Akt1 gene was also present in Drosophila tumors
developed in the eye. We used this model to confirm the effects of curcumin analogue, C-150
on modulating the Notch/Akt signaling pathway in vivo. Under our experimental conditions
about 60% of the animals kept on media having either water or ethanol developed tumors
(58.7%, n = 104; 61.7%, n = 162, respectively) (Fig 7). When mitoxantrone or carboplatin (1
mg/l) was applied a significant reduction of tumor-bearing animals could be recorded (37.6%,
n = 178, and 28.3%, n = 92, respectively). C-150 was dissolved in ethanol and mixed into the
medium at two concentrations (1 mg/l and 10 mg/l). Mutant Drosophila flies were grown on
supplemented media and malignant phenotype was recorded. As seen in Fig 7 C-150 resulted
Fig 6. Kinase profiling of C-150. The effects of C-150 (1μM) on kinase inhibition was examined on a kinase panel of numerous different kinases. Note the
significant inhibition of PKC-alpha.
doi:10.1371/journal.pone.0149832.g006
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in concentration-dependent reduction of tumor occurrence. At lower concentration C-150
decreased tumor incidence by almost 30% (malignant phenotype was recorded in 42.9% of the
animals; n = 182), while 10 mg/l C-150 resulted in 42% decrease when compared to control
groups (35.6% tumor incidence, n = 132).
In vivo effects of C-150 in orthotopic glioma xenograft
The in vivo effectiveness of C-150 was tested against intracerebrally implanted human glioblas-
toma cells (U87 MG) in the nude rat xenograft model. To circumvent bioavailability problems,
we used a liposome delivery system for the encapsulation of C-150 and intravenous
administration.
Animals treated with C-150 displayed a significantly longer median survival time (27 days)
compared to control animals (36 days, p = 0.0181) (Fig 8).
Conclusions
Malignant gliomas are associated with a poor prognosis due to inherent drug and radiation
resistance, therefore more effective therapeutic agents with less side effects are urgently needed.
The present study demonstrated a potent, cell death-inducing effect of C-150, an analogue of
the natural compound, curcumin, in human glioma cells.
Fig 7. In vivo effect of C-150 on aDrosophila double Akt/Notch „gain-of-expression”mutant strain. (a)
Malignant transformation occurs in the eye. (b) Tumor incidence is presented for each control and treated
group (sample size is indicated for each group overlaid on the columns). Error bars represent standard
deviation from 3 independent measurements. All treatments had a p value below 0.01 when compared to
their respective controls (Student’s t-test).
doi:10.1371/journal.pone.0149832.g007
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Cytotoxic effects of C-150 were mediated by affecting multiple targets as confirmed at tran-
scription and protein level. C-150 effectively reduced the transcription activation of NF-κB in
an in vitromodel, a result that may be beneficial in glioblastoma where NF-κB is constitutively
over-expressed. C-150 also decreased the expression of genes implicated in cytoprotection and
chemo-resistance [51, 52]. Curcumin has been previously shown to activate UPR and induce
ER-stress and subsequent apoptosis of tumor cells. Here we demonstrated that C-150 was at
least 30-times more potent than curcumin to induce the expression of key genes and their pro-
tein products in initiation and execution phases of ER stress at low- and sub-micromolar con-
centrations. In a kinase panel consisting of 28 different kinases C-150 inhibited PKC-alpha, a
kinase that has been implicated in tumors of the CNS, including glioblastoma. Among the tar-
gets of curcumin, the Akt/mTOR and Notch pathways have preferential roles in cancer cell
proliferation. C-150 was able to decrease Drosophila tumorigenesis in their eye in a double
Akt/Notch „gain-of-expression”mutant strain verifying that this pathway is modulated by C-
150, although the affected targets seem to be other than mTOR and AKT1, since the biochemi-
cal assay testing kinase inhibition showed no effect in case of these two kinases. Finally, C-150
significantly increased the survival of treated rats in a glioma animal model compared to vehi-
cle control.
Increased potency compared to curcumin, the demonstrated multi-target action and the




Glioblastoma cells (U373 MG, U87 MG, GBM1-GBM6 cell lines were a kind gift from Balazs
Hegedus, Semmelweis University, Hungary, [53] while the U251 MG cell line was a gift from
Szabolcs Bellyei, University of Pecs, originally obtained from American Type Culture Collec-
tion, Manassas, VA) were grown at 37°C under 5% of CO2 and 100% humidity in DMEM and
RPMI medium supplemented with 10% fetal calf serum (FCS) (Sigma-Aldrich), and penicillin-
Fig 8. In vivo effects of C-150 in orthotopic glioma xenograft. Kaplan-Meier survival curves of rats
intracerebrally grafted with U87-MG cells and treated with C-150. Time is expressed in days from inoculation.
Animals treated with C-150 displayed a significantly longer median survival time compared to control animals
(27 vs. 36 days, n = 7 in both groups, p = 0.0181 Log-rank (Mantel-Cox) Test).
doi:10.1371/journal.pone.0149832.g008
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streptomycin antibiotics. For cytotoxicity assays, 10,000 cells were seeded into each well of
96-well cell culture plates in culture medium containing 10% FCS. Effects of curcumin and C-
150 were recorded 48 h after treatment. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazo-lium) reagent was applied to drug treated and
control (0.2% DMSO) cells (CellTiter 961 AQueous Assay, Promega, Madison, WI) according
to the manufacturer’s protocol.
Holographic cell analysis
Digital holographic images were taken by the HoloMonitor M3 instrument (Phase Holo-
graphic Imaging AB, Phiab, Sweden). Four different glioma cell lines (U87 MG, U-251 MG,
GBM1, GBM2) were treated with 1.0 μMC-150 in T25 flasks and incubated for 24 hours.
Holographic images were captured of the same culture area before and after treatment. Cell
morphological changes were analyzed by Holostudio 2.4 software (Phase Holographic Imaging
AB, Phiab, Sweden). Each point in the scatter plot represents data of a single cell.
Western blot analysis
U87 MG cells were lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mMNaCl, 1% NP-40,
1% sodium deoxy-cholate, 0.1% SDS) containing 1% (v/v) mammalian protease inhibitor cock-
tail from Sigma and separated on 10% SDS-PAGE, following by transferring to a nitrocellulose
or PVDF (Immobilon-P Transfer Membranemembrane, Millipore). The membrane was then
blocked in blocking buffer (20 mM Tris-HCl, 150 mMNaCl, 0.1% Tween-20, 10% milk) for
overnight (16 hours) at room temperature. After blocking, corresponding primary antibody
was incubated for one hour, followed by a 45 minute incubation with the corresponding HRP-
conjugated secondary antibody at room temperature. Extensive washes with a blocking buffer
were performed between each step. The protein immuno-complex was visualized by Super-
Signal West PICO Chemiluminescent Substrate (Thermo Scientific). Dilutions for the primary
antibodies were as follows: anti-GADD 153 mouse monoclonal antibody (sc-7351, Santa Cruz)
at 1:200, anti-GRP78 rabbit polyclonal antibody (sc-13968, Santa Cruz) at 1:1000, anti-p-Akt1/
2/3 (Ser 473) rabbit polyclonal antibody (sc-7985, Santa Cruz) at 1:200, anti-β-actin mouse
monoclonal antibody (sc-47778, Santa Cruz) at 1:200.
Gene-expression analysis by QRT-PCR
Total RNA was purified from 400,000 of curcumin, C-150 treated and control (0.2% DMSO)
cells (6 h after treatment) with AccuZolTM RNA purification kit (Bioneer, Daeleon, Korea)
according to the manufacturers’ protocol. Three independent treatments were carried out with
each condition. Total RNA (2 μg) was converted into cDNA with the High-Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA) in a total volume of 20 μl, and without puri-
fication the mixture was diluted five times and 2 μl was applied to QRT-PCR analysis.
QRT-PCR was performed on The LightCycler1Nano Instrument (Roche). Expression of S18
rRNA and GRP78 were measured with corresponding TaqMan Gene Expression Assays (Life
Technologies, Cat. # 4331182 and Cat. # 4331182), while GADD153, ATF4 and XBP1 expres-
sion were measured with the SybrGreen protocol using the following primers: GADD153_F:
5’-cagagctggaacctgaggag-3’; GADD153_R: 5’-tggatcagtctggaaaagca-3’; ATF4_F: 5’-tctccagcga-
caaggctaa-3’; ATF4_R: 5’-caatctgtcccggagaagg-3’; XBP1_F: 5’-ggagttaagacagcgcttgg-3’;
ATF4_F: 5’-tctccagcgacaaggctaa-3’; ATF4_R: 5’- caatctgtcccggagaagg-3’; XBP1_R: 5’-cactggcct-
cacttcattcc-3’ [54]. Relative expression ratios were normalized to S18 rRNA. For significance
analysis Student’s t-test was applied in Excel.
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NF-κB Activation Assay
The B16 cell line was maintained in RPMI medium (Lonza) supplemented with 10% FCS
(Lonza). The NF-κB reporter cell lines were created by transfection with the pNF-κB-Luc/neo
reporter construct with the Lipofectamine 2000 reagent (Invitrogen) [55]. Stable cell lines were
selected by G418 (Sigma) treatment.
B16/NF-κB-Luc cells, grown on luminoplates (Corning-Costar) were used. Cells (5×104
cells/well) were treated with C-150 or curcumin (or vehicle control) after 30 min of NF-κB
induction by TNFα (10 ng/ml). After 6 hours of incubation with inducers, the medium was
removed, the cells were washed and lysed for 10 min at room temperature in Cell Culture Lysis
Reagent (20 μl/well; Promega). Substrate was added (20 μl/well; Promega), and luciferase activ-
ity was measured in a Luminoskan Ascent (Thermo Electron Corporation) scanning lumin-
ometer. Cell viability was routinely determined using trypan blue exclusion test during the
assays to make sure that assays were always carried out on viable cells.
Kinase profiling of C-150
Selectivity panel measurements were performed by Proteros biostructures GmbH (Germany) on
selected kinases. Assays were based on either IMAP-FP (Molecular Devices) or Reporter Dis-
placement Assay (RDA) (Proteros) [56]. In cases of b-Raf, DDR1 and mTOR RDA were used, in
other cases IMAP-FP were applied. Protocol for IMAP-FP (substrate finder) assays: reaction vol-
umes were 8 μl/well in a 384-well black plate. Final assay concentrations: kinase concentration
yielding 50% substrate turnover. ATP: adjusted to Kmapp. Substrate: 400 nM, type of substrate
was adjusted to different kinases. Protocol for RDA assays (a high-throughput binding assay for
affinity, kinetic and thermodynamic profiling): reaction volumes were 15 μl/well in a 384-well
black plate. Final assay concentrations of the kinases: b-Raf 9.0 nM, DDR1 15.0 nM, mTOR 8.0
nM. Reporter Probe: adjusted to reporter probe Kd. C-150 was screened at 1 μM concentration.
Fly stocks and drug treatment
To generate ey-Gal4<UAS-Dl/+; GS1D233C(Akt)/+ flies, frequently exhibiting eye tumors, we
crossed w1118; ey-Gal4<UAS-Dl/CyO, twi-GFP females to w1118; GS1D233C(Akt)/TM3, twi-
GFPmales. From the progeny of this cross we collected the freshly hatched “non-green” larvae
that were distributed into test vials containing 5 ml of standard fly food supplemented with C-
150 dissolved in ethanol or the corresponding solvent as control. Each chemical was tested in
at least three independent vials, eye phenotypes were analyzed in few days old adult flies. For
significance analysis Student’s t-test was applied in Excel.
Liposome encapsulation of C-150
Liquid-phase C-150 containing liposomes were prepared by dissolving lipid powder CHOL/PC/DSPE-
mPEG (62/28/0.6 mol%) and C-150 (9.2 mol%) in EtOH. After the solvent had been removed, the
lipid film was hydrated and redispersed in PBS solution to a final C-150 concentration of 1 mg/ml.
The dispersion was subjected to size extrusion (0.45 μmpore size) and finally filtered through sterile
filters (0.22 μmpore size). The droplet size, SSA and PDI of the liposomes were measured by laser
diffractometry (n = 5) by the wet method. The d(0.1), d(0.5) as median and d(0.9) droplet sizes, SSA
and PDI were 75 ± 19 nm, 114 ± 20 nm, 178 ± 24 nm, 54.5 m2/g and 0.901 ± 0.20, respectively.
In vivo orthotopic glioma xenograft
Female nude rats (RNU rats, Charles River, Hungary) were housed in sterile cages. They
were fed autoclaved food and sterile water ad libitum. For inoculation U87 MG cells were
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trypsinized, washed and resuspended in sterile PBS. 106 Cells were injected intracerebrally. All
animals were treated moribund and were euthanized at the observation of the first sign of tor-
ment. All operative procedures and animal care conformed strictly to the Hungarian Council
on Animal Care guidelines.
Animals were randomized and two groups, control (n = 7) and treated (n = 7) were created.
The administration of C-150-containing liposomes into the tail veins started on day 4 and was
continued 3 times a week for 4 weeks at one-sixth of the tolerated dose: 3 mg/kg. For signifi-
cance analysis Log-rank (Mantel-Cox) test was applied in GraphPad Prism.
Supporting Information
S1 Table. QRT-PCR results. Table showing all of the QRT-PCR experiments performed with
C-150 at various concentrations. The second table shows statistical significances of corre-
sponding gene expression changes (Student’s t test).
(PDF)
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